{{Expert-subject|Pharmacology|date=March 2010}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458271650
| IUPAC_name =
<!-- Clinical data -->
| tradename = Apidra
| Drugs.com = {{drugs.com|monograph|insulin_glulisine}}
| MedlinePlus = a607033
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = POM
| legal_US = Rx-only
| legal_status =
| routes_of_administration = Subcutaneous
<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 207748-29-6
| ATC_prefix = A10
| ATC_suffix = AB06
| PubChem =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01309
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 7XIY785AZD
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04540
<!-- Chemical data -->
| C=258 | H=384 | N=64 | O=78 | S=6
| molecular_weight = 5823 g/mol
}}
'''Insulin glulisine''' is a rapid-acting [[insulin analogue]] that differs from human [[insulin]] in that the amino acid [[asparagine]] at position B3 is replaced by [[lysine]] and the lysine in position B29 is replaced by [[glutamic acid]].<ref>DailyMed: [http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=7137 apidra (insulin glulisine)  injection, solution]</ref> It was developed by [[Sanofi-Aventis]] and is sold under the trade name '''Apidra'''.<ref>{{cite book|title=Austria-Codex|editor=Jasek, W|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2007|edition=2007/2008|isbn=978-3-85200-181-4|language=German}}</ref> When injected subcutaneously, it appears in the blood earlier than human insulin.<ref>{{Cite journal | last1 = Garnock-Jones | first1 = K. P. | last2 = Plosker | first2 = G. L. | doi = 10.2165/00003495-200969080-00006 | title = Insulin Glulisine | journal = Drugs | volume = 69 | issue = 8 | pages = 1035–1057 | year = 2009 | pmid =  19496630| pmc = }}</ref> When used as a meal time insulin, the dose is to be administered within 15 minutes before or 20 minutes after starting a meal.<ref>Drugs.com: [http://www.drugs.com/monograph/insulin-glulisine.html Insulin Glulisine]</ref> Intravenous injections may also be used for extreme hyperglycemia, but must be performed under the supervision of a medical professional.<ref>{{cite web|first=Sanofi|title=Sanofi Prescription Products|url=http://products.sanofi.us/apidra/apidra.pdf|publisher=Sanofi|accessdate=21 April 2012}}</ref>

==References==
{{reflist}}

==External links==
*[http://products.sanofi-aventis.us/apidra/apidra.html Apidra Homepage]

{{Oral hypoglycemics and insulin analogs}}
{{Peptidergics}}

[[Category:Insulin therapies]]